Tuberculosis (TB) is currently responsible for more deaths per annum than any other pathogen (1).
Despite modest gains in control in recent years, the rate of progress is too slow. Data from mathematical modelling suggests that an effective vaccination strategy will be required to achieve the ambitious targets described in the SDGs and the Stop TB Partnership's Global Plan to End TB (2). The recent results from the M72/AS01e efficacy trial give us some cause for optimism (3) . The M72/AS01e protein/adjuvant vaccine candidate achieved 49.7% efficacy (95% CI, 2.1 to 74.2), in preventing TB disease in Mycobacterium tuberculosis (M.tb) latently infected subjects. This is a landmark result for the field and provides proof-of-concept that it is possible to protect against TB disease with vaccination. However, more data is needed, in particular on how effective this vaccine is in protecting against TB disease in those uninfected with M.tb. The confidence intervals in this trial are wide and further efficacy data is likely to be necessary before this vaccine is licensed and deployed. Whilst three-
year efficacy data of 49% is better than anything else achieved to date, we should not rest on our laurels. A more effective vaccine would be better.
Two key challenges in TB vaccine development are the lack of predictive preclinical animal models and the absence of validated immunological correlates of protection. In other fields where vaccine development is complex, such as malaria, the use of controlled human infection models has complemented preclinical and human immunology studies and facilitated vaccine development (4) . Here, Davids et al have established a human experimental medicine of bronchoscopic installation of either purified protein derivative (PPD) or BCG (5) . BCG is the only licensed vaccine against TB and confers highly variable efficacy against pulmonary disease (6) . As BCG is a live attenuated strain of Page 2 of 6 AJRCCM Articles in Press. Published on 06-January-2020 as 10.1164/rccm.201912-2408ED Copyright © 2020 by the American Thoracic Society M.bovis, it provides a potential surrogate human challenge agent for use in a controlled human infection model. This work builds on earlier work in which PPD delivered intrabronchially resulted in an influx of Th1 CD4+ T cells 48 hours later (7) . Davids et al recruited subjects within a spectrum of pre-existing mycobacterial exposure, from asymptomatic household contacts who were interferon gamma release assay negative, through to subjects with multiple previous, fully treated episodes of microbiologically proven TB disease. Importantly, the incidence of adverse events in this study was low and the intervention appeared to be safe. All adverse events were mild and managed in an outpatient setting. The authors go on to use the bronchoalveolar lavage fluid collected prior to installation of PPD/BCG, together with a repeat lavage taken three days after installation, to interrogate the host immune response. They demonstrate alterations in innate cells and total IgG at the highest BCG dose administered and an increased frequency of CD4+ interferon gamma+ T cells after the highest dose of PPD. Furthermore, the authors also show differential gene expression and a dysregulated protein response after BCG and PPD installation. These BAL-specific responses were not detected in the peripheral blood, suggesting considerable compartmentalisation of the response. 
